Neumora Therapeutics (NMRA) Other Non Operating Income (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Other Non Operating Income of $59000.0 for Q1 2026, up 336.0% year-over-year from $13532.1 in Q1 2025, and down 98.79% quarter-over-quarter from $4.9 million in Q4 2025.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $59000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 336.0% year-over-year to $59000.0; the TTM figure through Mar 2026 stood at $4.5 million (up 5000.0% YoY), while the FY2025 annual figure was $4.4 million, up 5708.97% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $59000.0, down from $4.9 million in the prior quarter.
- The five-year high for Other Non Operating Income was $4.9 million in Q4 2025, with the low at -$480000.0 in Q2 2025.
- The 5-year median for Other Non Operating Income is -$24000.0 (2024), against an average of $288333.3.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income sank 5600.0% in 2024, then surged 32386.67% in 2025.
- Neumora Therapeutics' Other Non Operating Income stood at $287000.0 in 2022, then sank by 136.24% to -$104000.0 in 2023, then surged by 114.42% to $15000.0 in 2024, then soared by 32386.67% to $4.9 million in 2025, then sank by 98.79% to $59000.0 in 2026.
- Business Quant data shows NMRA's Other Non Operating Income at $59000.0 in Q1 2026, $4.9 million in Q4 2025, and $7000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,000.00 |
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | 6.92 Mn |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -480,000.00 |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -24,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -104,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -39,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | 287,000.00 |
| Sep 30, 2022 | -148,000.00 |